Can we use stem cells to fight Malaria?

Lisa Anderson
Former President, American University of Cairo (AUC)
Share:
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Future of Global Health and Healthcare

Human stem cells engineered to produce renewable sources of mature, liver-like cells can be grown and infected with malaria to test potentially life-saving new drugs, according to researchers at the Massachusetts Institute of Technology.

The advance comes at a time when the parasitic mosquito-borne disease, which kills nearly 600,000 people every year, is showing increased resistance to current treatment, especially in Southeast Asia, according to the World Health Organization.

The liver-like cells, or hepatocytes, in the MIT study were manufactured from stem cells derived from donated skin and blood samples.

The resulting cells provide a potentially replenishable platform for testing drugs that target the early stage of malaria, when parasites may linger and multiply in the liver for weeks before spreading into the bloodstream.

Sangeeta Bhatia, a biomedical engineer and senior author of the MIT report, told the Thomson Reuters Foundation that the breakthrough study not only showed that these liver-like cells could host a malaria infection but also described a way to mature the young cells so that an adult-like metabolism, necessary for drug development, could be established.

The study is published in the Feb. 5 online issue of Stem Cell Reports.

Stem cells retain the genetic makeup of their donors, affording researchers the potential to test drugs against a large variety of genetic types and a variety of diseases.

“This allows us to explore in depth how different diseases affect different people, in this case malaria,” Bob Palay, chairman and CEO of Cellular Dynamics International (CDI), told the Thomson Reuters Foundation.

“This allows you to study it in a dish and find new drugs,” he added, noting that CDI uses blood samples for its stem cells.

Before this development, researchers tested new drugs using human liver cells from cadavers and cancerous liver cells.

“In both cases, they don’t work as well, not the same thing as healthy living cells,” said Palay.

Malaria, caused by parasites transmitted through mosquito bites, causes fever, chills and other flu-like symptoms and can be fatal if not diagnosed and treated early.

Key ways to prevent malaria include insecticide-treated mosquito nets for beds and indoor spraying with insecticides.

There were about 198 million cases of malaria in 2013, according to the latest WHO estimates.

Malaria mortality rates have dropped by nearly half globally and by 54 percent in Africa since 2000, but the WHO estimated that a child in Africa dies every minute from the disease.

This article is published in collaboration with Thomson Reuters Foundation trust.org. Publication does not imply endorsement of views by the World Economic Forum.

To keep up with the Agenda subscribe to our weekly newsletter.

Author: Lisa Anderson is the North America correspondent for the Thomson Reuters Foundation

Image: Malaria tests are seen on a table in the Ta Gay Laung village hall in Hpa-An district in Kayin state, south-eastern Myanmar, November 28, 2014. REUTERS/Astrid Zweynert.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

About Us

Events

Media

Partners & Members

  • Sign in
  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum